![JCM | Free Full-Text | Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation JCM | Free Full-Text | Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation](https://www.mdpi.com/jcm/jcm-13-01073/article_deploy/html/images/jcm-13-01073-g001.png)
JCM | Free Full-Text | Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation
![Hematology Review on X: "How to switch between anticoagulants "Old and New" https://t.co/hH1Ay4Zm4N" / X Hematology Review on X: "How to switch between anticoagulants "Old and New" https://t.co/hH1Ay4Zm4N" / X](https://pbs.twimg.com/media/C77Tg2uXwAA3Vs2.jpg)
Hematology Review on X: "How to switch between anticoagulants "Old and New" https://t.co/hH1Ay4Zm4N" / X
![JCM | Free Full-Text | Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation JCM | Free Full-Text | Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation](https://www.mdpi.com/jcm/jcm-10-02866/article_deploy/html/images/jcm-10-02866-g004.png)
JCM | Free Full-Text | Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
CorConsult Rx - #Repost @ambcarerx ・・・ Oral Anticoagulants have many chronic indications, most commonly VTE treatment/prophylaxis, atrial fibrillation, and valvular heart disease. VTE & AF can both be treated with either warfarin
Guidance for Switching from Warfarin to Direct-acting Oral Anticoagulants (DOACs) for patients with Non-Valvular - Atrial Fibril
![Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study | BMC Primary Care | Full Text Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study | BMC Primary Care | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12875-022-01824-6/MediaObjects/12875_2022_1824_Fig3_HTML.png)
Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study | BMC Primary Care | Full Text
![Switching from warfarin to NOAC. NOAC, non-vitamin K antagonist oral... | Download Scientific Diagram Switching from warfarin to NOAC. NOAC, non-vitamin K antagonist oral... | Download Scientific Diagram](https://www.researchgate.net/publication/330931168/figure/fig2/AS:723659262025728@1549545221292/Switching-from-warfarin-to-NOAC-NOAC-non-vitamin-K-antagonist-oral-anticoagulant-INR.png)
Switching from warfarin to NOAC. NOAC, non-vitamin K antagonist oral... | Download Scientific Diagram
![Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs43044-022-00259-9/MediaObjects/43044_2022_259_Fig3_HTML.png)